How Biomedical & Pharma teams in Singapore automate repetitive work with AI while respecting the PDPA and sector rules — implemented by dgm on osFoundry.
dgm is an independent osFoundry integration partner — not affiliated with osFoundry’s maker (OS LLC), and dgm has no completed client integrations yet.
Automation is where AI pays for itself in biomedical & pharma — but the goal is a measurable reduction in manual work on a specific workflow, not ‘AI everywhere’. Here is a sensible way to approach it in Singapore.
What to automate first in biomedical & pharma
Good first candidates are high-volume, repeatable and text- or data-heavy: AI-driven drug discovery and target identification, clinical-trial document automation and pharmacovigilance signal detection are typical. Avoid starting with one-off or highly bespoke work — the return is harder to prove.
A practical automation sequence
- Pick one repetitive biomedical & pharma workflow — for example AI-driven drug discovery and target identification — and write down the current steps and time spent.
- Set a baseline so you can measure improvement, and confirm where the data lives and whether it must stay in Singapore.
- Build a small automation with a human in the loop, check its output against the regulator expectations that apply, then expand.
| Stage | Focus |
|---|---|
| Scope | One workflow, current steps, time spent |
| Baseline | Measurable starting point + data-residency check |
| Pilot | Human-in-the-loop build, checked against compliance |
| Expand | Roll out once value is proven |
Compliance while you automate
The Health Sciences Authority (HSA) is the national regulator for health products, handling pre-market evaluation and GMP inspections; sector development is driven by EDB. HSA’s GL-04 guidelines (Revision 4, December 2025) cover software and machine-learning-enabled medical devices. Singapore is an end-to-end biopharma manufacturing and R&D hub, so AI in drug development and manufacturing operates under strict GMP and HSA device oversight. Because there is no standalone binding AI Act in force in 2026, the constraints to design around are the PDPA (consent, notification, protection and the PDPC’s AI advisory guidelines), the Cybersecurity Act where critical infrastructure is involved, and the sector rules above.
Keeping automation in Singapore
GxP data integrity and regulated processes often require controlled or in-region environments. osFoundry’s managed cloud pins data to the US, EU or Japan — it does not currently offer a Singapore managed region (its nearest managed region is Japan). For data that must stay in Singapore, the honest path is self-hosting osFoundry (BYO Cloud) inside a Singapore cloud region such as AWS Asia Pacific (Singapore) ap-southeast-1, Microsoft Azure Southeast Asia (Singapore) or Google Cloud asia-southeast1 (Singapore), or running models locally on-device. osFoundry can run your chosen model under one layer and be self-hosted in a Singapore region or run locally for sensitive workflows.
Where dgm fits
dgm is an independent integration partner that helps Singapore businesses adopt osFoundry — scoping a first use case, handling the build, and connecting AI to the systems you already run. dgm can build the first biomedical & pharma automation with you and keep a human in the loop. dgm is independent of osFoundry’s maker (OS LLC) and has no completed client integrations yet, so everything described here is a service offered, not a past result. If you want to scope a practical first project, dgm can help you map it out.